Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC002 (DermaVir Vaccine) in HIV-1-Infected Subjects on HAART
NCT00270205Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2006
- Primary completion
- Sep 2010
- Modality
- Nanoparticles, DNA Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DermaVir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2006; status: completed.
02
Drugs
DermaVir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00270205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270205.